## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

No clear thesis: MRS_10 at 4.4%, does not meet entry criteria. Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($261.17)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. ATTENTION CI SHAREHOLDERS: Investors Who Lost Money on The Cigna Group are Urged to Contact Levi & Korsinsky About an Ongoing Investigation**
- Source: WJTV | 20251217T120752 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into The Cigna Group (NYSE:CI) concerning potential violations of federal securities laws. This follows Cigna's Q3 2025 earnings report, which revealed a higher Healthcare Medical Care Ratio (MCR) of 84.8% compared to 82.8% in Q3 2024, leading to a significant drop in the company's stock price by 17% on October 30, 2025. Investors who suffered losses are encouraged to contact Levi & Korsinsky for more information regarding the ongoing investigation.

**2. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T010759 | Bullish | Relevance: 100%
- This article analyzes Cigna Group (NYSE: CI) to determine if its current stock price reflects its long-term potential, suggesting it might be undervalued. Using a Discounted Cash Flow (DCF) analysis, the intrinsic value is estimated at $1,062 per share, indicating a significant 74.0% discount. Additionally, its current Price-to-Earnings (PE) ratio of 12.0x is well below industry averages, further supporting the undervaluation thesis based on its Fair Ratio framework.

**3. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T012346 | Bullish | Relevance: 100%
- Cigna Group (NYSE:CI) is currently trading at what appears to be a significant discount, with a valuation score of 5/6 and a potential 74.0% undervaluation based on discounted cash flow analysis. The stock also trades at a lower Price/Earnings ratio (12.0x) compared to the broader healthcare industry (23.9x) and its peer group (31.2x), suggesting it is undervalued given its earnings growth outlook. Investors can explore "Narratives" on Simply Wall St to understand different assumptions influencing Cigna's fair value.

**4. CI STOCK ALERT: Levi & Korsinsky Notifies The Cigna Group Investors of an Ongoing Investigation**
- Source: ACCESS Newswire | 20251215T140756 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) for potential federal securities law violations. This investigation follows CI's third-quarter 2025 earnings report, which revealed an increase in their Healthcare MCR to 84.8% from 82.8% in 2024, attributed to their Individual and Family Plans business and higher stop loss medical costs. This news led to a 17% drop in CI's stock price on October 30, 2025.

**5. Rep. Julie Johnson Sells International Paper Company (NYSE:IP) Shares**
- Source: MarketBeat | 20251215T132120 | Neutral | Relevance: 74%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of International Paper Company (NYSE:IP) shares on November 3rd, 2025, from her Merrill Lynch account. The company previously missed quarterly EPS expectations but reported a 56.4% revenue growth and announced a quarterly dividend of $0.4625. International Paper currently holds a consensus "Hold" rating with a $50.44 price target from analysts.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 9.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 9.0x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.1B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 9.0 |
| Current P/E | 9.2 |
| YoY Growth | 3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.0% to 4.4% (+3.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 77th percentile. MRS_5 at 1.5% confirms short-term momentum alignment. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (1.28), confirming momentum. RSI neutral at 51. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.42% (CS: 78) | Strong |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | 1.28 | Bullish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.981x | Below |
| vs SMA200 | 0.906x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $273.75
- **Stop Loss:** $261.17 (4.6% risk)
- **Target:** $286.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $23,268.75
- **Portfolio %:** 23.27%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*